Tag: orexin

Clinical Insights & Research Narcolepsy Patient Advocacy & Awareness Patient Health SleepWorld Magazine

Awakenings from WUN: Making Sense of the Science of Narcolepsy

It’s a very exciting time in narcolepsy research, particularly on two fronts: better understanding the complexities of the disorder and developing more targeted treatments. With so many advances underway, it can feel overwhelming to keep track of research developments and understand how the pieces fit together. This can be especially […]

FDA Approves Takeda’s ORZEYFUL for Narcolepsy Type 1
Global News Industry News Narcolepsy Pharmacological

U.S. FDA Approves Takeda’s ORZEYFUL, the First and Only Orexin Agonist for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. […]

Takeda's ORZEYFUL Approved in China for Narcolepsy Type 1
Narcolepsy Pharmacological

New Study: Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for Narcolepsy Type 1

New data presented by Takeda at SLEEP 2026 this week continues to build the case for oveporexton (TAK-861) as a potential disease-modifying treatment for narcolepsy type 1 (NT1). Oveporexton is designed to address the root cause of the disease, targeting the underlying orexin deficiency responsible for NT1. Results from two pivotal […]